Page 43 - JCTR-11-3

Journal of Clinical and
Translational Research Immunogenicity and safety of flu vaccines

doi: 10.1080/21645515.2016.1182270 42. Eun BW, Lee TJ, Lee J, et al. A randomized, double-blind,
active-controlled Phase III trial of a cell culture-derived
37. Vesikari T, Kirstein J, Devota Go G, et al. Efficacy, quadrivalent inactivated influenza vaccine in healthy
immunogenicity, and safety evaluation of an MF59- South Korean children and adolescents 6 months to 18 years
adjuvanted quadrivalent influenza virus vaccine compared of age. Pediatr Infect Dis J. 2019;38:e209-e215.
with non-adjuvanted influenza vaccine in children: A
multicentre, randomised controlled, observer-blinded, doi: 10.1097/INF.0000000000002406
phase 3 trial. Lancet Respir Med. 2018;6:345-356. 43. Oh CE, Choi UY, Eun BW, et al. A randomized, double-
doi: 10.1016/S2213-2600(18)30108-5 blind, active-controlled clinical trial of a cell culture-derived
inactivated trivalent influenza vaccine (NBP607) in healthy
38. McBride WJH, Abhayaratna WP, Barr I, et al. Efficacy of children 6 months through 18 years of age. Pediatr Infect Dis
a trivalent influenza vaccine against seasonal strains and J. 2018;37:605-611.
against 2009 pandemic H1N1: A randomized, placebo-
controlled trial. Vaccine. 2016;34:4991-4997. doi: 10.1097/INF.0000000000001973
doi: 10.1016/j.vaccine.2016.08.038 44. Moehling KK, Zimmerman RK, Nowalk MP, et al.
A randomized controlled trial of antibody response to
39. Frey SE, Reyes MR, Reynales H, et al. Comparison of the 2018-19 cell-based vs. egg-based quadrivalent inactivated
safety and immunogenicity of an MF59®-adjuvanted with influenza vaccine in children. Vaccine. 2020;38:5171-5177.
a non-adjuvanted seasonal influenza vaccine in elderly
subjects. Vaccine. 2014;32:5027-5034. doi: 10.1016/j.vaccine.2020.06.023
doi: 10.1016/j.vaccine.2014.07.013 45. Nolan T, Chotpitayasunondh T, Capeding MR, et al.
Safety and tolerability of a cell culture derived trivalent
40. Cowling BJ, Perera RAP, Valkenburg SA, et al. Comparative subunit inactivated influenza vaccine administered to
immunogenicity of several enhanced influenza vaccine healthy children and adolescents: A Phase III, randomized,
options for older adults: A randomized, controlled trial. Clin multicenter, observer-blind study. Vaccine. 2016;34:230-236.
Infect Dis. 2020;71:1704-1714.
doi: 10.1016/j.vaccine.2015.11.040
doi: 10.1093/cid/ciz1034
46. Diez-Domingo J, de Martino M, Lopez JG, et al. Safety and
41. Loeb M, Russell ML, Kelly-Stradiotto C, et al. Adjuvanted tolerability of cell culture-derived and egg-derived trivalent
trivalent influenza vaccine versus quadrivalent inactivated influenza vaccines in 3 to <18-year-old children and
influenza vaccine in Hutterite Children: A randomized adolescents at risk of influenza-related complications. Int J
clinical trial. Vaccine. 2021;39:6843-6851. Infect Dis. 2016;49:171-178.
doi: 10.1016/j.vaccine.2021.10.035 doi: 10.1016/j.ijid.2016.06.018

Volume 11 Issue 3 (2025) 37 doi: 10.36922/JCTR025060006